ArticleIJTLD open2026
Community-led monitoring of TB services in the Kyrgyz Republic.
Article in IJTLD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTB remains a major public health challenge in the Kyrgyz Republic due to continued transmission and drug resistance. Despite an overall decline in incidence, gaps persist in case notification, procurement processes, and patient-centred care.
methodsThis study reports on the first community-led monitoring (CLM) initiative for TB services, implemented by TB People Kyrgyzstan in partnership with KNCV KG from 2019 to 2024. Programmatic data were combined with structured interviews of people with TB, community monitors, and health workers to identify barriers to diagnosis, treatment, and access to medicines.
resultsEstimated TB incidence declined over the study period, yet under-notification remained substantial, with 56.5% of cases not notified in 2024. Procurement was generally stable; however, regulatory and customs delays limited access to new medicines. Patients reported stigma, transport costs, and limited psychosocial support as key barriers, while health workers highlighted shortages of trained staff in rural areas.
conclusionCLM complemented national surveillance by amplifying community perspectives and identifying actionable priorities. Expanding access to rapid diagnostics, strengthening procurement coordination, investing in the TB workforce, and sustaining community engagement are essential to accelerate progress towards End TB targets. This approach supports equity, improvement, and resilience.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.